GtoPdb Ligand ID: 6881

Synonyms: Actemra® | R-1569 | RG-1569 | RHPM-1 | RoActemra®
tocilizumab is an approved drug (FDA (2010), EMA (2009))
Compound class: Antibody
Comment: Tocilizumab is an anti-IL-6 receptor mAb, with immunosuppressive action [6] that is approved for chronic autoimmune indications.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Qyuns Therapeutics have a potential tocilizumab biosimilar (QX003S) in Phase 1 evaluation for rheumatoid arthritis (trial registry number ChiCTR1900021808).

In early March 2020, China's National Health Commission issued guidance that allows use of tocilizumab to treat patients with serious COVID-19-induced lung damage. Tocilizumab is predicted to mitigate against the uncontrolled immune response that is triggered by SARS-CoV-2 infection in some patients and which leads to potentially life-threatening lung damage.
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: tocilizumab

1. Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J et al.. (2006)
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.
Arthritis Rheum., 54 (9): 2817-29. [PMID:16947782]
2. Matsuyama M, Suzuki T, Tsuboi H, Ito S, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Sumida T. (2007)
Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.
Intern. Med., 46 (11): 771-4. [PMID:17541233]
3. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, Matsumoto Y, Ohsugi Y. (2005)
Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
Int. Immunopharmacol., 5 (12): 1731-40. [PMID:16102523]
4. Nishimoto N, Kishimoto T. (2008)
Humanized antihuman IL-6 receptor antibody, tocilizumab.
Handb Exp Pharmacol, (181): 151-60. [PMID:18071945]
5. Ohsugi Y, Kishimoto T. (2008)
The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis.
Expert Opin Biol Ther, 8 (5): 669-81. [PMID:18407769]
6. Paul-Pletzer K. (2006)
Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.
Drugs Today, 42 (9): 559-76. [PMID:17028666]
7. Unizony S, Kermani TA. (2018)
IL-6 Blockade and its Therapeutic Success in Giant Cell Arteritis.
J Neuroophthalmol, 38 (4): 551-558. [PMID:30199509]
8. Yokota S, Miyamae T, Imagawa T, Katakura S, Kurosawa R, Mori M. (2005)
Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis.
Clin Rev Allergy Immunol, 28 (3): 231-8. [PMID:16129907]